The first osimertinib trough concentration (Ctrough) was 82.1 ng/mL, significantly lower than the FDA-reported 166 ng/mL, with concurrent elevation of the tumor marker carcinoembryonic antigen (CEA). Here, CEACAM5 is linked to neoplasm.